May 2012 issue
Cover illustration: The co-crystal structure of botulinum neurotoxin serotype A light chain with a potent peptide inhibitor RRGF (p. 511). The active site of the toxin and its bound peptide inhibitor with electron density is shown here. Molecular interactions of the toxin with various peptide inhibitors were mapped, the structure-activity relationship was derived and a pharmacophore model was developed. This study could lead to the discovery of drugs against the most potent toxin known, botulinum neurotoxin.